Search for:
  • Sign in
  • Register
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
Monday, June 9, 2025
PharmaBoardroom
Sign In Register
  • Home
  • Country Reports
    • All
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Exclusive interviews
    • All
    • Latest
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Articles
    • All
    • Global
    • Latest
  • Legal & Regulatory
    • All
    • The Pharma Legal Handbook
    • Regulatory, Pricing and Reimbursement
    • Marketing, Manufacturing, Packaging and Labeling
    • Preclinical and Clinical Trials
  • Op-Eds & Contributions
  • InFigures
    • All
    • Rankings
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Library
    • All
    • InFocus
    • InFigures
    • White Papers
  • Media Kit
  • Register
  • About Us
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
Lithuania Pharma Report 2018 Download

Lithuania,

March 2018

Despite a tiny domestic market size, the Lithuanian life sciences sector is full of hidden surprises. Comprising four percent of the nation’s entire GDP, with one percent accounted for by a burgeoning biotechnology sector, Lithuania can draw on a strong science R&D infrastructure and a talented domestic labor pool.

 

The multinational affiliate leaders, heads of significant local players, key opinion leaders, government officials, and regulators featured in this report unpack these topics, along with a range of others including the country’s outstanding potential in clinical trials, the possibilities of acting as a biotech hub for the Baltics, and how companies are drawing on Lithuania’s heritage as one of the world’s leading manufacturers of lasers.

Despite a tiny domestic market size, the Lithuanian life sciences sector is full of hidden surprises. Comprising four percent of the nation’s entire GDP, with one percent accounted for by a burgeoning biotechnology sector, Lithuania can draw on a strong science R&D infrastructure and a talented domestic labor pool.

 

The multinational affiliate leaders, heads of significant local players, key opinion leaders, government officials, and regulators featured in this report unpack these topics, along with a range of others including the country’s outstanding potential in clinical trials, the possibilities of acting as a biotech hub for the Baltics, and how companies are drawing on Lithuania’s heritage as one of the world’s leading manufacturers of lasers.

See more

Legal & Regulatory

report
Buy
Tags:
Lithuania, Baltics, Healthcare, Pharma, Biotech
Share on Facebook Share on WhatsApp Share on Twitter Share on Linkedin Share in Email
Back
PharmaBoardroom

PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Latest

  • Articles
  • In Conversation
  • Facts & Figures
  • Country Reports
  • Legal & Regulatory
  • InFocus

More

  • About Us

Join Us

  • Email Newsletters
  • LinkedIn

Contact

+44 2078673717

info@stage.pharma.kalyna.dev

Legal & Privacy

  • Terms and Conditions
  • Privacy and Cookies policy
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

logo

Sign in

Forgot password? Register Now